当前位置: 首页 > 期刊 > 《中国医学创新》 > 2015年第17期
编号:12556835
个体性化疗方案在耐药肺结核患者治疗中的应用研究(3)
http://www.100md.com 2015年6月15日 《中国医学创新》 2015年第17期
     在三种治疗方案中都出现了不良反应。化疗过程中,大剂量、多种类药物的应用会导致肝、肾、胃肠道以及关节等的损害,尤以肝损害严重[17]。除了定期对患者进行肝功能检查之外,还要应用一些护肝药物,加强护肝治疗。对其他症状的发生,应及时给予相应的对症治疗,以使患者能够完成整个疗程的抗结核治疗。耐药肺结核病患者肺内伴有广泛纤维病变,厚壁空洞等不可逆病变,而且患者常反复感染、咯血,因此,需密切监护患者,防止各种并发症的发生[18]。除此之外,肺结核疾病的传染性也应引起重视,尤其是咯血患者,应严格执行消毒隔离制度,防止院内感染等情况的发生。

    参考文献

    [1]胡克.结核病影响因素研究进展[J].中国医学创新,2013,10(4):160-162.

    [2] Burns K E,Liu W T,Boshoff H I,et al.Proteasomal protein degradation in Mycobacteria is dependent upon a prokaryotic ubiquitin-like protein[J].Journal of Biological Chemistry,2009,284(5):3069-3075.
, http://www.100md.com
    [3]李芳.支气管结核单纯化疗和介入综合治疗近期效果观察[J].中国医学创新,2013,10(10):44-45.

    [4] Striebel F,Imkamp F,Sutter M,et al.Bacterial ubiquitin-like modifier Pup is deamidated and conjugated to substrates by distinct but homologous enzymes[J].Nature Structural & Molecular Biology,2009,16(6):647-651.

    [5]万轲.左氧氟沙星和利福平治疗初治肺结核的临床疗效比较[J].中国医学创新,2012,9(23):51-52.

    [6] Sutter M,Striebel F,Damberger F F,et al.A distinct structural region of the prokaryotic ubiquitin-like protein (Pup) is recognized by the N-terminal domain of the proteasomal ATPase Mpa[J].FEBS letters,2009,583(19):3151-3157.
, 百拇医药
    [7] Wang T,Darwin K H,Li H.Binding-induced folding of prokaryotic ubiquitin-like protein on the Mycobacterium proteasomal ATPase targets substrates for degradation[J].Nature Structural & Molecular Biology,2010,17(11):1352-1357.

    [8] Burns K E,Pearce M J,Darwin K H.Prokaryotic ubiquitin-like protein provides a two-part degron to Mycobacterium proteasome substrates[J].Journal of Bacteriology,2010,192(11):2933-2935.

    [9] Striebel F,Hunkeler M,Summer H,et al.The mycobacterial Mpa-proteasome unfolds and degrades pupylated substrates by engaging Pup’s N-terminus[J].The EMBO Journal,2010,9(7):1262-1271.
, http://www.100md.com
    [10] Imkamp F,Rosenberger T,Striebel F,et al.Deletion of dop in Mycobacterium smegmatis abolishes pupylation of protein substrates in vivo[J].Molecular Microbiology,2010,75(3):744-754.

    [11] Cerda-Maira F A,Pearce M J,Fuortes M,et al.Molecular analysis of the prokaryotic ubiquitin-like protein (Pup) conjugation pathway in Mycobacterium tuberculosis[J].Molecular Microbiology,2010,77(5):1123-1135.

    [12] Darwin K H.Prokaryotic ubiquitin-like protein (Pup),proteasomes and pathogenesis[J].Nat Rev Microbiol,2009,7(7):485-491.
, 百拇医药
    [13] Sutter M,Damberger F F,Imkamp F,et al.Prokaryotic ubiquitin-likeprotein (Pup) is coupled to substrates via the side chain of its C-terminal glutamate[J].Journal of the American Chemical Society,2010,132(16):5610-5612,[14] Reyes-Turcu R E,Ventii K H,Wilkinson K D.Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes[J].Annual Review of Biochemistry,2009,78(6):363-397.

    [15] Wilkinson K D.DUBs at a glance[J].Journal of Cell Science,2009,122(14):2325-2329.
, 百拇医药
    [16] Burns K E,Cerda-Maira F A,Wang T,et al.Depupylation of prokaryotic ubiquitin-like protein from mycobacterial proteasome substrates[J].Molecular Cell,2010,39(5):821-827.

    [17] Imkamp F,Striebel F,Sutter M,et al.Dop functions as a depupylase in the prokaryotic ubiquitin-like modification pathway[J].EMBO Reports,2010,11(10):791-797.

    [18] Vandal O H,Nathan C F,Ehrt S.Acid resistance in Mycobacterium tuberculosis[J].Journal of Bacteriology,2009,191(15):4714-4721.

    (收稿日期:2015-01-05) (本文编辑:蔡元元), 百拇医药(张绿洲)
上一页1 2 3